These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 35024314)

  • 1. Antibody-drug conjugates: Recent advances in linker chemistry.
    Su Z; Xiao D; Xie F; Liu L; Wang Y; Fan S; Zhou X; Li S
    Acta Pharm Sin B; 2021 Dec; 11(12):3889-3907. PubMed ID: 35024314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Analysis of Key Factors Related to ADCs Structural Design.
    Tang H; Liu Y; Yu Z; Sun M; Lin L; Liu W; Han Q; Wei M; Jin Y
    Front Pharmacol; 2019; 10():373. PubMed ID: 31068807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction to Antibody-Drug Conjugates.
    Pettinato MC
    Antibodies (Basel); 2021 Oct; 10(4):. PubMed ID: 34842621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions.
    Li C; Shi K; Zhao S; Liu J; Zhai Q; Hou X; Xu J; Wang X; Liu J; Wu X; Fan W
    Pharmacol Res; 2024 Sep; 207():107341. PubMed ID: 39134188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azobenzene-Based Linker Strategy for Selective Activation of Antibody-Drug Conjugates.
    Xiao D; Liu L; Xie F; Dong J; Wang Y; Xu X; Zhong W; Deng H; Zhou X; Li S
    Angew Chem Int Ed Engl; 2024 Apr; 63(16):e202310318. PubMed ID: 38369681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.
    Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M
    J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety.
    Wang Y; Liu L; Fan S; Xiao D; Xie F; Li W; Zhong W; Zhou X
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
    Frigerio M; Kyle AF
    Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.
    Sheyi R; de la Torre BG; Albericio F
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy
    Su D; Zhang D
    Front Pharmacol; 2021; 12():687926. PubMed ID: 34248637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.
    Balamkundu S; Liu CF
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers.
    Salomon PL; Reid EE; Archer KE; Harris L; Maloney EK; Wilhelm AJ; Miller ML; Chari RVJ; Keating TA; Singh R
    Mol Pharm; 2019 Dec; 16(12):4817-4825. PubMed ID: 31609629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry.
    Fujii T; Matsuda Y
    Expert Opin Biol Ther; 2023; 23(11):1053-1065. PubMed ID: 37953519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Chemistry Behind ADCs.
    Kostova V; Désos P; Starck JB; Kotschy A
    Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34067144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances and Limitations of Antibody Drug Conjugates for Cancer.
    Mckertish CM; Kayser V
    Biomedicines; 2021 Jul; 9(8):. PubMed ID: 34440076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates.
    Watanabe T; Arashida N; Fujii T; Shikida N; Ito K; Shimbo K; Seki T; Iwai Y; Hirama R; Hatada N; Nakayama A; Okuzumi T; Matsuda Y
    J Med Chem; 2024 Oct; 67(20):18124-18138. PubMed ID: 39410752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
    Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
    Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates.
    Tedeschini T; Campara B; Grigoletto A; Bellini M; Salvalaio M; Matsuno Y; Suzuki A; Yoshioka H; Pasut G
    J Control Release; 2021 Sep; 337():431-447. PubMed ID: 34329685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.